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Quality of life assessment in female patients 2 
and 4 years after muscle-derived cell transplants 
for stress urinary incontinence treatment
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 Abstract 
Introduction: Regenerative medicine for the treatment of urinary incontinence has become a popular area of focus 
in the search for therapies for this disease. The paper focused on women’s quality of life assessment who were 
subjected to transplantation of MDSC (autologous muscle derived stem cells)  to the urethral sphincter. 
Methods: The procedure was conducted in 16 female patients who completed the observation stage. Assessment 
of quality of life before and after the treatment (two and four years post-operation) was conducted based on the 
validated I-QOL questionnaire (the Polish language version).
Results: The questionnaire study showed that autologous cell therapy signiﬁcantly improves quality of life in female 
patients suﬀering from stress urinary incontinence (SUI). The total I-QOL score increased from 49 (SD ± 7.7) before 
therapy to 77 (SD ± 5.4) two years post-operation. Four years after the procedure, quality of life remained at a higher 
level than before therapy, although quality of life decreased by several points when compared with the results from 
the two-year follow-up – 63 (SD ± 7.2). Patients reported signiﬁcantly less concern related to their ability to reach 
the toilet to avoid incontinence, improved sleep at night, a higher level of satisfaction with life, and more satisfaction 
with their sexual lives (p<0.05). 
Conclusion: The MDSC injection procedure for SUI treatment has signiﬁcant improved quality of life in the majority 
of our patients in 2 and 4 year follow-up.
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 Streszczenie        
Cel pracy: Medycyna regeneracyjna w leczeniu nietrzymania moczu stała się popularnym obszarem zainteresowania 
w poszukiwaniu metod leczenia tej choroby. Celem niniejszej pracy była ocena jakości życia u kobiet poddanych 
transplantacji autologicznych dojrzałych komórek pochodzących z mięśni (MDSC) do zwieracza cewki moczowej.
Materiał i metody: Badanie zostało przeprowadzone w grupie 16 pacjentek, które ukończyły etap obserwacji. Do 
oceny jakości życia przed i po leczeniu (w dwa i cztery lata po zabiegu) wykorzystano kwestionariusz I-QOL (polska 
wersja językowa).
Wyniki: Badania ankietowe wykazało, że terapia z  wykorzystaniem autologicznych komórek mięśniowych 
w  znacznym stopniu poprawia jakość życia pacjentek cierpiących z powodu wysiłkowego nietrzymania moczu 
(WNM). Całkowity wynik I-QOL wzrósł z 49 ± 7,7 (SD) przed leczeniem do 77 (SD ± 5,4) dwa lata po zabiegu. 
Cztery lata po zabiegu, jakość życia pozostał na poziomie wyższym niż przed leczeniem, chociaż zmniejszyła się 
o kilka punktów w porównaniu z wynikami z dwóch lat obserwacji - 63 (SD ± 7,2). Pacjentki zgłaszały znacznie 
mniej objawów związanych z  ich możliwością dotarcia do toalety, wyższy poziom zadowolenia z  życia i więcej 
satysfakcji z życia seksualnego (p <0,05).
Wnioski: Zastosowana procedura MDSC do leczenia wysiłkowego nietrzymania moczu skutecznie poprawiła 
jakość życia u większości analizowanych pacjentek po 2 i 4 latach od zbiegu.
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Table  I I .   Summary of questionnaire responses (I-QOL) related to avoidance and limiting behavior to assess the quality of life of patients before (y0) and after cell 
transplantation (y2 –2 years after treatment, y4 –4 years after treatment). 
I-QOL questions
I-QOL score Fisher test;p-value





































58 83 77 0.2967 0.6743 0.9155
4 	
 38 78 59 0.0007211 0.1179 0.2569
10 
toilet. 38 73 58 0.004844 0.1753 0.5563
11 

	important to plan every detail in advance. 59 84 70 0.04821 0.08051 0.5579
13 I have a hard time getting a good night of sleep 	





	 48 72 61 0.02683 0.4244 0.4748
Table  I I I .  Summary of questionnaire responses (I-QOL) for the group of questions related to psychosocial impacts to assess the quality of life of female patients before (y0) 
and after cell transplantation (y2 - after 2 years, y4 - after 4 years).
I-QOL questions
I-QOL score Fisher test;p-value






















I don’t feel free to leave my home for long periods of 
time.




	incontinence prevent me from doing what I want. 53 77 64 0.05104 0.06639 0.5857
9 !
	my mind. 44 75 59 0.005987 0.06639 0.5647
15 !
	like I’m not a healthy person. 47 72 61 0.2503 0.587 0.8921
16 !




problems or incontinence. 47 75 64 0.01035 0.05359 0.7848
21 !




problems or incontinence. 59 83 73 0.007611 0.01848 0.7888
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Figure 1. Incidence of patients responding to the questions related to avoidance and limiting behavior. The charts refer to data for which the result of the statistical study was 
signiﬁcant (p<0.05). y0 – black (before treatment); y2 – light gray (2 years after treatment); y4 – gray (4 years after treatment).
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Figure 2. Incidence of female patients responding to questions related to psychosocial impacts. The charts refer to data for which the result of the statistical study was signiﬁcant 
(p<0.05). y0 – black (before treatment); y2 – light gray (2 years after treatment); y4 – gray (4 years after treatment).
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Table  IV.  Summary of questionnaire responses (I-QOL) corresponding to social embarrassment questions to assess the quality of life of female patients before (y0) and after 
cell transplantation (y2 - 2 years after treatment, y4 - 4 years after treatment).
I-QOL questions
I-QOL score Fisher test;p-value


















 48 78 58 0.07711 0.5374 0.4114
12 	






	 55 78 58 0.3735 0.5988 0.5413
18 	
 47 72 58 0.03846 0.08956 0.3501
19 I feel like I have no control over my bladder. 42 72 56 0.02707 0.05051 0.2773
 
Figure 3. Incidence of female patients responding to the questions related to social embarrassment (SE). The charts refer to data for which the results of the statistical study were 
signiﬁcant at two years after the treatment (p<0.05). y0 – black (before treatment); y2 – light gray (2 years after treatment); y4 – gray (4 years after treatment).
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